Biotech Startup Investment Held Steady Even As AI Funding Surged
While the AI boom has disrupted funding patterns across the startup sphere, biotech has remained a rare steady sector for investment. For the past few years, global funding to biotech startups has hovered between $36 billion and $40 billion. Per Crunchbase data, 2026 is on track to stay close to that range.
While the AI boom has disrupted funding patterns across the startup sector, biotech has remained a steady sector for investment. For the past few years, global funding to biotech startups has consistently hovered between $36 billion and $40 billion. Despite an overall record level of venture investment in the first half of this year, biotechs secured a respectable share of the remaining funds.
A few biotechs picked up large financings. AI-focused biotechs garnered over $6 billion this year, with large rounds including Isomorphic Labs' $2.1 billion Series B, Earendil Labs' $787 million, and Chai Discovery's $400 million. Other notable AI-focused fundraisers include NewLimit, a longevity startup, which raised $435 million.
While many heavily funded biotechs are at later stages, the overall startup pipeline remains early-stage, with more than half of investment going to seed and early-stage rounds. Some biotechs have gone public early, such as Kailera Therapeutics, Kardigan, and Latigo Biotherapeutics.
Later-stage biotechs also participated in IPOs, including Parabilis Medicines, a cancer therapeutics company. Biotech startups delivered significant M&A exits as well, with 12 transactions valued at $1 billion or more. Overall, biotech funding and exits remain healthy, even though conditions appear tame compared to the AI investment exuberance.
Written by urgent.news from Crunchbase News's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
